Q3 2021 Investor Relations Results

Financial review Conclusion Appendix Participants Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview 2021 key pipeline milestones¹ H1 2021 References Innovation: Clinical trials Achieved Readout not supportive Regulatory decisions EntrestoⓇ HFpEF (US) H2 2021 CosentyxⓇ Pediatric psoriasis (US/CN/JP) and opinions KesimptaⓇ Relapsing MS (EU/JP) Major Leqvio® Hyperlipidemia (US)² ✓ Asciminib (ABL001) CML 3L (JP) expected JakaviⓇ submissions TabrectaⓇ Acute and chronic GVHD (EU/JP) ✓ NSCLC (EU) BeovuⓇ DME (JP) Alpelisib (BYL719) BeovuⓇ DME (US/EU) H2 KymriahⓇ Asciminib (ABL001) CML 3L (US/EU) ✓ CosentyxⓇ JIA (US/EU) Major expected trial readouts* Iptacopan (LNP023) Ph2 - IgAN Iptacopan (LNP023) Ph2 - C3G ✓ H2 ECF843 177 Lu-PSMA-617 Tislelizumab (VDT482) Tislelizumab (VDT482) Canakinumab (ACZ885) PROS (US) r/r Follicular lymphoma (US/EU✓ JP) mCRPC (US ✓/EU) 2L esophageal cancer (US) NSCLC (US/EU) Ph3 - NSCLC 1L Ph2 - Dry eye EntrestoⓇ Ph3 - Post-AMI 5 Ligelizumab (QGE031) Ph3 - CSU6 Canakinumab Ph3 NSCLC 2L 7 KisqaliⓇ Ph3 - ABC (MONALEESA-2 OS) (ACZ885) 177Lu-PSMA-617 Cosentyx® Ph3 - mCRPC Ph3 - JIA ✓ Remibrutinib (LOU064) CosentyxⓇ Ph2 - CSU Ph3 - HS ✓ ✓ H1-20223 ✓ 9 ✓ *Achieved Sabatolimab (MBG453) Ph2 - MDS8 KymriahⓇ Ph3 aNHL 2L 7 on-time readout of data, irrespective of trial outcome. 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities. 2. Resubmitted to FDA 3. H1 2022 MAA submission, evaluation of US BLA submission options ongoing. 4. Program discontinued in broad population of moderate to severe DED. 5. Numerical trends consistently favored EntrestoⓇ vs. active comparator but did not meet primary composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned. 6. Q4/2021-Q1/2022 potential COVID impact. 7. Negative readout 8. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial 9. Ph3 study did not meet primary endpoints. PFS and OS trends support further evaluation with additional analyses ongoing 50 Investor Relations | Q3 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation